New Insight on Preventing EGFR Inhibitor –Induced Adverse Effects

Targeted drugs that bind to and inhibit the epidermal growth factor receptor (EGFR) profoundly benefit many patients with solid tumors without the severe adverse effects associated with chemotherapy and radiation. But the agents can cause stigmatizing facial rashes and other cutaneous symptoms that may decrease cancer treatment adherence and effectiveness. Now, new research published in Science Translational Medicine reveals the mechanisms behind these adverse effects and points to an add-on treatment that might help to prevent them.
Source: JAMA - Category: General Medicine Source Type: research